254 Results
Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.
A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.
Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
BioConference Live has selected Biodesix to present at the 5th annual Life Sciences conference, taking place online on October 26–27.
Data show that VeriStrat was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies.
Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.
The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.
Biodesix, Inc., today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado.
Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).